Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.

5 Oct 2009

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter International Inc. today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein.

From Baxter International Inc. 5 Oct 2009

Innovative health care information technology solutions to improve quality of patient care

Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), provided the integrated solution to help Methodist reduce the length of stay associated with patients and help realize gains in efficiency and revenue.

5 Oct 2009

PrimeraDx receives its fourth patent

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled “Methods and systems for dynamic gene expression profiling”, with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization".

5 Oct 2009

Diagnocure signs agreement with Lab21 for marketing its Previstage test

DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.

5 Oct 2009

New genetic alteration can cause familial cancers

Duke University Medical Center and National Cancer Institute scientists have discovered that a novel genetic alteration - a second copy of an entire gene - is a cause of familial chordoma, an uncommon form of cancer arising in bones and frequently affecting the nervous system.

5 Oct 2009

$APP Pharmaceutical continues support of FDA's USP standards for unfractionated heparin$

APP Pharmaceutical continues support of FDA's USP standards for unfractionated heparin

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ), and the leading supplier of heparin sodium to the U.S. market, announced today its continued support of the US Food & Drug Administration (FDA) and medical community for the October 1, 2009 implementation of the new United States Pharmacopeia (USP) monograph change for unfractionated heparin.

3 Oct 2009

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

3 Oct 2009

Researchers study the role of CHRNA3 and CHRNA5 genes in lung cancer

A recent study published in the October 2009 issue of the Journal of Thoracic Oncology determined that variations of specific genetic markers identified in previous research, or SNPs, may indicate a greater lung cancer risk in African Americans than in whites. The genes CHRNA3 and CHRNA5 may contribute to lung cancer risk due directly or through their association with nicotine dependence.

3 Oct 2009

CHI announces its speaker lineup for the 2009 California Healthcare Policy Forum

California Healthcare Institute today announced its speaker lineup for the 2009 California Healthcare Policy Forum to be held Nov. 5, at the InterContinental Mark Hopkins San Francisco Hotel, from 11:30 a.m. to 6:00 p.m.

3 Oct 2009

University HealthSystem Consortium awards UH Case Medical Center the 2009 Quality Leadership Award

University Hospitals (UH) Case Medical Center is one of five academic medical centers in the nation to receive the 2009 Quality Leadership Award from the University HealthSystem Consortium (UHC). The prestigious award is given to teaching hospitals that demonstrate excellence in delivering high-quality care, as measured by the UHC Quality and Accountability Study conducted annually since 2005.

3 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

New strategic research service for the oncology market launched by Health Strategies Group

Health Strategies Group, a leading provider of market intelligence to the pharmaceutical and biotechnology industries, has just launched Oncology Performance Edge, a new strategic research service that helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources.

3 Oct 2009

Research study reveals primary chemotherapy benefits

Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Z-rich showed that patients in primary therapy benefit to the same extent from chemotherapy alone as from radiation alone.

3 Oct 2009

Celldex Therapeutics acquires CuraGen Corporation

Celldex Therapeutics, Inc. announced today the successful completion of its acquisition of CuraGen Corporation (Nasdaq: CRGN) pursuant to the previously disclosed Agreement and Plan of Merger, dated as of May 28, 2009, by and among CuraGen, Celldex and Celldex’s merger subsidiary, Cottrell Merger Sub, Inc.

3 Oct 2009

BioDelivery Sciences International files NDS for BEMA Fentanyl

BioDelivery Sciences International, Inc.today announced the filing of a New Drug Submission (NDS) to Health Canada, the regulatory authority in Canada, for BEMA Fentanyl, also known as fentanyl buccal soluble film. BEMA Fentanyl is marketed in the U.S. as ONSOLIS, and the Canadian tradename is to be determined.

3 Oct 2009

Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study

Telik, Inc. today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10.

3 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

Oncology News and Research

Further Reading

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Innovative health care information technology solutions to improve quality of patient care

PrimeraDx receives its fourth patent

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Diagnocure signs agreement with Lab21 for marketing its Previstage test

New genetic alteration can cause familial cancers

APP Pharmaceutical continues support of FDA's USP standards for unfractionated heparin

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

Researchers study the role of CHRNA3 and CHRNA5 genes in lung cancer

CHI announces its speaker lineup for the 2009 California Healthcare Policy Forum

University HealthSystem Consortium awards UH Case Medical Center the 2009 Quality Leadership Award

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

New strategic research service for the oncology market launched by Health Strategies Group

Research study reveals primary chemotherapy benefits

Celldex Therapeutics acquires CuraGen Corporation

BioDelivery Sciences International files NDS for BEMA Fentanyl

Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News